99 related articles for article (PubMed ID: 25033978)
1. Therapeutic and survival outcomes following treatment of primary central nervous system lymphoma: a 12-year case study.
Sitthinamsuwan B; Rujimethapass S; Chinthammitr Y; Treetipsatit J
J Neurosurg Sci; 2014 Sep; 58(3):183-90. PubMed ID: 25033978
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
5. A multicenter study of treatment of primary CNS lymphoma.
Ferreri AJ; Reni M; Pasini F; Calderoni A; Tirelli U; Pivnik A; Aondio GM; Ferrarese F; Gomez H; Ponzoni M; Borisch B; Berger F; Chassagne C; Iuzzolino P; Carbone A; Weis J; Pedrinis E; Motta T; Jouvet A; Barbui T; Cavalli F; Blay JY
Neurology; 2002 May; 58(10):1513-20. PubMed ID: 12034789
[TBL] [Abstract][Full Text] [Related]
6. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases.
Hodson DJ; Bowles KM; Cooke LJ; Kläger SL; Powell GA; Laing RJ; Grant JW; Williams MV; Burnet NG; Marcus RE
Clin Oncol (R Coll Radiol); 2005 May; 17(3):185-91. PubMed ID: 15901003
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Primary Central Nervous System Lymphoma with High-dose Methotrexate and Radiotherapy in HIV-negative Patients.
Jalaeikhoo H; Yekaninejad MS; Hajizamani S; Rahim F; Ahmadzadeh A; Keyhani M; Sadeghi Hariri B; Saki N
Arch Iran Med; 2015 Sep; 18(9):577-81. PubMed ID: 26317598
[TBL] [Abstract][Full Text] [Related]
9. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
12. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
Karmali R; Nabhan C; Petrich AM; Raizer J; Peace D; Lukas R; Gordon LI; Basu S; Chukkapalli V; Venugopal P
Br J Haematol; 2017 Apr; 177(1):72-79. PubMed ID: 28211579
[TBL] [Abstract][Full Text] [Related]
13. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.
Ferreri AJ; Blay JY; Reni M; Pasini F; Spina M; Ambrosetti A; Calderoni A; Rossi A; Vavassori V; Conconi A; Devizzi L; Berger F; Ponzoni M; Borisch B; Tinguely M; Cerati M; Milani M; Orvieto E; Sanchez J; Chevreau C; Dell'Oro S; Zucca E; Cavalli F
J Clin Oncol; 2003 Jan; 21(2):266-72. PubMed ID: 12525518
[TBL] [Abstract][Full Text] [Related]
14. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
16. Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.
Cobert J; Hochberg E; Woldenberg N; Hochberg F
J Neurooncol; 2010 Jul; 98(3):385-93. PubMed ID: 20020180
[TBL] [Abstract][Full Text] [Related]
17. Results of treatment of 112 cases of primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients with primary central nervous system lymphoma treated outside clinical trials.
Hart A; Baars JW; Kersten MJ; Brandsma D; van Tinteren H; de Jong D; Spiering M; Dewit L; Boogerd W
Neth J Med; 2014 May; 72(4):218-23. PubMed ID: 24829178
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Poortmans PM; Kluin-Nelemans HC; Haaxma-Reiche H; Van't Veer M; Hansen M; Soubeyran P; Taphoorn M; Thomas J; Van den Bent M; Fickers M; Van Imhoff G; Rozewicz C; Teodorovic I; van Glabbeke M;
J Clin Oncol; 2003 Dec; 21(24):4483-8. PubMed ID: 14597741
[TBL] [Abstract][Full Text] [Related]
20. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
Korfel A; Martus P; Nowrousian MR; Hossfeld DK; Kirchen H; Brücher J; Stelljes M; Birkmann J; Peschel C; Pasold R; Fischer L; Jahnke K; Thiel E;
Br J Haematol; 2005 Jan; 128(2):177-83. PubMed ID: 15638851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
